4SC AG Valor Contábil/Ação
Qual é o Valor Contábil/Ação de 4SC AG?
O Valor Contábil/Ação de 4SC AG é 0.76
Qual é a definição de Valor Contábil/Ação?
O valor contábil por ação é um ativo da empresa menos as responsabilidades dividido pelo número de ações em circulação.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valor Contábil/Ação de empresas na Setor Health Care em XETRA em comparação com 4SC AG
O que 4SC AG faz?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Empresas com valor contábil/ação semelhantes a 4SC AG
- Farmmi Inc tem Valor Contábil/Ação de 0.75
- Hennes & Mauritz AB tem Valor Contábil/Ação de 0.75
- Guyana Goldfields tem Valor Contábil/Ação de 0.76
- SEM tem Valor Contábil/Ação de 0.76
- Euroland Corporate Societe anonyme tem Valor Contábil/Ação de 0.76
- Goldshore Resources tem Valor Contábil/Ação de 0.76
- 4SC AG tem Valor Contábil/Ação de 0.76
- NovoCure Ltd tem Valor Contábil/Ação de 0.76
- Japara Healthcare tem Valor Contábil/Ação de 0.76
- Acorn Capital Investment Fund tem Valor Contábil/Ação de 0.76
- Taizhou Water Co Ltd tem Valor Contábil/Ação de 0.76
- Lyra Therapeutics tem Valor Contábil/Ação de 0.76
- Vulcan Steel Ltd tem Valor Contábil/Ação de 0.76